Lindus Health and Quotient Sciences have joined forces to make it easier to find patients for medical studies and speed up the process of developing new drugs. This partnership is designed to help drug companies work more efficiently by combining the strengths of both companies. Quotient has expertise in early drug development and runs over 70 initial studies each year in the US and UK. Lindus specializes in finding patients for these studies and has access to over 40 million medical records. Together, they will streamline the drug development process, reducing delays and making it easier for drug companies to bring new medicines to patients. Michael Young, co-CEO of Lindus, said, ‘This partnership helps remove roadblocks in drug development. By working with Quotient, we’re creating a smooth path for drug companies to move from early to later stages of testing.’ Matt Paterson, chief strategy officer at Quotient, added, ‘This partnership allows for faster development and decision-making, getting new drugs to patients more quickly.’